Deferiprone

Deferiprone

Systematic (IUPAC) name
3-hydroxy-1,2-dimethylpyridin-4(1H)-one
Clinical data
Trade names	Ferriprox
AHFS/Drugs.com	International Drug Names
Licence data	EMA:Link, US FDA:link
Pregnancy category	US: D (Evidence of risk)
Legal status	US: ℞-only
Routes of administration	Oral
Pharmacokinetic data
Metabolism	Glucuronidation
Biological half-life	2 to 3 hours
Excretion	Renal (75 to 90% in 24 hours)
Identifiers
CAS Number	30652-11-0 Y
ATC code	V03AC02 (WHO)
PubChem	CID: 2972
IUPHAR/BPS	7456
ChemSpider	2866 Y
UNII	2BTY8KH53L Y
KEGG	D07416 Y
ChEBI	CHEBI:68554 N
ChEMBL	CHEMBL70927 Y
Chemical data
Formula	C7H9NO2
Molecular mass	139.152 g/mol
SMILES O=C\1C(\O)=C(/N(/C=C/1)C)C
InChI InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3 Y Key:TZXKOCQBRNJULO-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Deferiprone (tradenames include Ferriprox) is a drug that chelates iron and is used to treat iron overload in thalassaemia major. It was first approved for use in treating thalassaemia major in 1994 and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States. On October 14, 2011, it was approved for use in the US under the FDA’s accelerated approval program.

Controversy

Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and the pharmaceutical company Apotex, that started in 1996 and delayed approval of the drug in North America. Dr. Olivieri's data suggested deferiprone leads to progressive hepatic fibrosis.

See also

• Deferoxamine
• Deferasirox